drugset / Trial / NCT05051930
A Clinical Trial of TQC3721 Suspension for Inhalation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease（COPD）and asthma.
Timeline
- Start
- 2021-10-18
- Primary completion
- 2022-10-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQC3721 | Unknown | 0.2 mg | Other |
| Subject | TQC3721 | Unknown | 1 mg | Other |
| Subject | TQC3721 | Unknown | 3 mg | Other |
| Subject | TQC3721 | Unknown | 6 mg | Other |
| Subject | TQC3721 | Unknown | 12 mg | Other |
| Subject | TQC3721 | Unknown | 24 mg | Other |